Colchicine in patients with aortic stenosis undergoing transcatheter aortic valve replacement: a double-blind randomized trial
Open Access
- 15 July 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Abstract
An inflammatory process may increase the risk of arrhythmias after transcatheter aortic valve replacement (TAVR). In this single-centre, double-blind, placebo-controlled, randomized trial we investigated the efficacy of colchicine to reduce a composite of new-onset atrial fibrillation or atrioventricular conduction disturbances requiring the implantation of a permanent pacemaker at 30 days after TAVR. Between September 21, 2021 and April 25, 2024, 120 patients with aortic stenosis undergoing TAVR (mean age 80.6 ± 5 years, 64% male) were randomly allocated to treatment with colchicine (n = 60) or placebo (n = 60). The trial was prematurely stopped due to a higher rate of stroke in the experimental group in a pre-specified interim analysis (5 [8.3%] versus 0 at maximum available follow-up, p = 0.022). In the intention-to-treat population, the primary endpoint occurred in 6 patients (10%) in the colchicine group and in 15 patients (25%) in the placebo group (risk-difference −15.0%, 95% CI −28.3 to −1.7, p = 0.031). The prespecified imaging endpoint, subclinical leaflet thrombosis, was detected in 13 of 48 patients (27%) in the colchicine group versus 26 of 48 patients (54%) in the placebo group (risk difference −27.1%. 95% CI −46.0% to −8.2%, p = 0.007). Here, we show that periprocedural treatment with colchicine may reduce the incidence of new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. However, given the premature termination of the trial due to an unexpected increase in the stroke rate among patients treated with colchicine, confirmatory trials are warranted to corroborate the effect of anti-inflammatory treatment on the incidence of arrhythmias and subclinical leaflet thrombosis after TAVR. The trial was an investigator-initiated study supported by dedicated grants from the Bangerter-Rhyner Foundation and the Swiss Life Foundation. ClinicalTrials.gov Identifier: NCT04870424.Keywords
Funding Information
- Gottfried und Julia Bangerter-Rhyner-Stiftung
- Jubiläumsstiftung der Schweizerischen Lebensversicherungs- und Rentenanstalt für Volksgesundheit und medizinische Forschung
This publication has 55 references indexed in Scilit:
- Clinical effects of permanent pacemaker implantation after transcatheter aortic valve implantation: Insights from the nationwide FRANCE-TAVI registryArchives of Cardiovascular Diseases, 2024
- Systemic inflammatory response syndrome in patients undergoing transcatheter aortic valve implantationCardiovascular Revascularization Medicine, 2023
- Systemic Corticosteroid Exposure and Atrioventricular Conductance Delays After Transcatheter Aortic Valve ImplantationCardiovascular Revascularization Medicine, 2022
- Management of Conduction Disturbances Associated With Transcatheter Aortic Valve ReplacementJACC, 2019
- Exposure to glucocorticoids prior to transcatheter aortic valve replacement is associated with reduced incidence of high-degree AV block and pacemakerCardiovascular Revascularization Medicine, 2019
- Colchicine for primary prevention of atrial fibrillation after open-heart surgery: Systematic review and meta-analysisInternational Journal of Cardiology, 2017
- Colchicine for prevention of post-cardiac procedure atrial fibrillation: Meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2017
- Colchicine: Old and NewThe American Journal of Medicine, 2015
- Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial FibrillationJAMA, 2014
- Autonomic nerve activity and atrial fibrillationHeart Rhythm, 2007